TLDR Ruxolitinib can cause a delayed skin reaction on the nose.
A 77-year-old woman developed a delayed granulomatous eruption on her nose after 5 years of ruxolitinib treatment for myelofibrosis. Despite various treatments, her condition worsened until ruxolitinib was discontinued, leading to complete resolution within 6 months. This case highlighted the potential for granulomatous drug eruptions (GDEs) associated with JAK inhibitors, emphasizing the need for awareness of such side effects as the use of these drugs increases in dermatology. The patient's granulomatous dermatitis resembled lupus pernio but lacked systemic sarcoidosis signs. The study underscored the importance of documenting JAK inhibitor side effects, given their emerging role in treating various dermatological conditions.
55 citations,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
116 citations,
February 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors help with skin conditions but need more research on dosing and safety.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
1 citations,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
37 citations,
September 2018 in “Journal of the American Academy of Dermatology” Ruxolitinib can help regrow hair in severe alopecia areata.
4 citations,
July 2018 in “PubMed” Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
